HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway

doi:10.1016/j.carbpol.2018.10.008

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药理学第三研究室

	HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway
	Yao, Yanli 1,3; Zhou, Lishuang 1,3; Liao, Wenfeng 1,3; Chen, Huanjun 1,3; Du, Zhenyun 1,3; Shao, Chenghao 2; Wang, Peipei1,3 ; Ding, Kan1,3
刊名	CARBOHYDRATE POLYMERS
	2019-01-15
卷号	204 页码:111-123
关键词	Polysaccharide Galectin-3 EGFR FOXO3 Pancreatic ductal adenocarcinoma
ISSN号	0144-8617
DOI	10.1016/j.carbpol.2018.10.008
文献子类	Article
英文摘要	Pancreatic ductal adenocarcinoma is a highly malignant gastrointestinal tumor. Molecular targeting therapy for pancreatic cancer is still limited. High expressed Galectin-3 in pancreatic cancer is positively correlated with disease progression, indicating that Galectin-3 can be employed as a predictor of poor prognosis. From safflower, we isolated and purified a homogeneous polysaccharide, HH1-1, which could bind to and inhibit Galectin-3. HH1-1 could block the interaction between Galectin-3 and EGFR. Following HH1-1 treatment, the binding ability between EGFR and Galectin-3 was reduced by 245.28 folds. HH1-1 could suppress pancreatic cancer cell proliferation, arrest the cell cycle in S phase, induce cell apoptosis, inhibit angiogenesis and impede tumor cell migration and invasion. Moreover, HH1-1 affected the Galectin-3/EGFR/AKT/FOXO3 signaling pathway and possessed anti-pancreatic cancer activity in vitro and in vivo, especially in patient-derived xenografts. Further study suggested that HH1-1 had almost no toxicity both in vitro and in vivo. This adds new evidence to suggest that HH1-1 could be a promising therapeutic agent and support the pursuit of the Galectin-3 as a target in pancreatic cancer treatment.
资助项目	Program of Shanghai Subject Chief Scientist[16XD1404500] ; National Natural Science Foundation of China (NSFC)[31670814] ; Shanghai Science and Technology Development Funds[14YF1407800]
WOS关键词	LUNG-CANCER ; DUCTAL ADENOCARCINOMA ; TRANSCRIPTION FACTORS ; CELL-CYCLE ; APOPTOSIS ; METASTASIS ; ANGIOGENESIS ; EXPRESSION ; GCS-100 ; INVOLVEMENT
WOS研究方向	Chemistry ; Polymer Science
语种	英语
出版者	ELSEVIER SCI LTD
WOS记录号	WOS:000448147100014
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279458]
专题	药理学第三研究室国家新药筛选中心
通讯作者	Wang, Peipei; Ding, Kan
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, Key Lab Receptor Res, Shanghai 201203, Peoples R China; 2.Second Mil Med Univ, Dept Gen Surg, Shanghai Changzheng Hosp, Shanghai 200030, Peoples R China 3.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China;
推荐引用方式 GB/T 7714	Yao, Yanli,Zhou, Lishuang,Liao, Wenfeng,et al. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway[J]. CARBOHYDRATE POLYMERS,2019,204:111-123.
APA	Yao, Yanli.,Zhou, Lishuang.,Liao, Wenfeng.,Chen, Huanjun.,Du, Zhenyun.,...&Ding, Kan.(2019).HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway.CARBOHYDRATE POLYMERS,204,111-123.
MLA	Yao, Yanli,et al."HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway".CARBOHYDRATE POLYMERS 204(2019):111-123.